Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lymphodepleting Chemotherapy Clear all
Not yet recruiting Phase 2 Interventional

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

NCT07137481
View directory record Official record
Conditions
Hematological Malignancies
Interventions
C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Suspended Phase 1 Interventional

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

NCT06447987
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Cetuximab, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1 Interventional

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

NCT06083883
View directory record Official record
Conditions
Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Interventions
Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

NCT06930651
View directory record Official record
Conditions
Myeloid Malignancies
Interventions
Dexamethasone, Cyclophosphamide, Fludarabine, Decitabine, TGFBR2 KO CAR27/IL-15 NK cells
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Suspended Phase 1Phase 2 Interventional

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

NCT05703854
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Interventions
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

CAR T-cell Therapy in Patients With Renal Dysfunction

NCT05909059
View directory record Official record
Conditions
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
Interventions
Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT05092451
View directory record Official record
Conditions
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Interventions
Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

NCT02280525
View directory record Official record
Conditions
Leukemia
Interventions
Lenalidomide, Rituximab, Fludarabine, Cyclophosphamide, NK Cells, Cytarabine
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

NCT01181258
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Rituximab, Interleukin-2, Natural killer cells, Cyclophosphamide, Methylprednisolone, Fludarabine
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 15, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

NCT00303836
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes, in vitro-treated peripheral blood stem cell transplantation, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, filgrastim, aldesleukin
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 15, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

NCT00670748
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
Interventions
Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide, fludarabine phosphate, ALVAC NY ESO-1 vaccine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Active, not recruiting Phase 1 Interventional

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

NCT07209241
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
CART-EGFR-IL13Ra2 T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

NCT03056339
View directory record Official record
Conditions
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Suspended Phase 1 Interventional

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

NCT03710421
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
CS1-CAR T Therapy, Cyclophosphamide, Fludarabine, Leukapheresis
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1 Interventional

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05052528
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Rituximab
Biological · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

NCT00138229
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 15, 2026, 1:16 PM EDT
Active, not recruiting Phase 1 Interventional

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

NCT02146924
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

NCT06847269
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

NCT05110742
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

NCT01875601
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers, Neuroblastoma
Interventions
Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 29 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 15, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 15, 2026, 1:16 PM EDT